Translational breast cancer research

IMPAKT 2009 and the future

Screening for breast cancer, how often?

Typical course for receptor positive early breast cancer

Bisphosphonates for breast cancer patients

Exemestane vs tamoxifen followed by exemestane

Bevacizumab plus docetaxel compared with placebo plus docetaxel for locally recurrent or metastatic breast cancer

Bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer

Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast cancer

A novel strategy in treating endocrine resistance using combination therapy

Sorafenib in combination with paclitaxel for locally recurrent or metastatic breast cancer

Fulvestrant 250 mg vs 500 mg in postmenopausal women with oestrogen receptor-positive advanced breast cancer